Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
| Brand name | AMOXICILLIN |
| Generic name | AMOXICILLIN |
| Active ingredient(s) | AMOXICILLIN |
| Distributed by / for | TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454 |
| NDC | 0093-4161-73 |
| Full product label | AMOXICILLIN for Oral Suspension USP, 400MG/5ML, 100ML (when reconstituted), Manufactured In Canada By: TEVA CANA LIMITED, Toronto, Canada M1B 2K9; Manufactured For: TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454. NDC: 0093-4161-73 |
| Recalling firm | CARDINAL HEALTHCARE |
| Distribution | Nationwide USA |
| Quantity | 3 units |
| Recall initiated | 2022-01-26 |
| Report date | 2024-01-03 |
| Recall completed | 2024-09-29 |
| Recall number | D-0165-2024 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Dublin OH United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗